Racial/Ethnic Differences in 25-Hydroxy Vitamin D and Parathyroid Hormone Levels and Cardiovascular Disease Risk Among Postmenopausal Women.
Aged
Biomarkers
/ blood
Cardiovascular Diseases
/ blood
Case-Control Studies
Ethnicity
Female
Follow-Up Studies
Forecasting
Humans
Incidence
Middle Aged
Parathyroid Hormone
/ blood
Postmenopause
/ blood
Prospective Studies
Racial Groups
Risk Assessment
/ methods
Risk Factors
United States
/ epidemiology
Vitamin D
/ analogs & derivatives
25(OH)D
biomarker
cardiovascular disease
parathyroid hormone/calcitonin
vitamin D
women
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
19 02 2019
19 02 2019
Historique:
entrez:
16
2
2019
pubmed:
16
2
2019
medline:
7
3
2020
Statut:
ppublish
Résumé
Background Recent evidence suggests that racial/ethnic differences in circulating levels of free or bioavailable 25-hydroxy vitamin D (25[ OH ]D) rather than total 25( OH )D may explain apparent racial disparities in cardiovascular disease ( CVD ). We prospectively examined black-white differences in the associations of total, free, and bioavailable 25( OH )D, vitamin D-binding protein, and parathyroid hormone levels at baseline with incident CVD (including nonfatal myocardial infarction, nonfatal stroke, and CVD death) in postmenopausal women. Methods and Results We conducted a case-cohort study among 79 705 postmenopausal women, aged 50 to 79 years, who were free of CVD at baseline in the WHI-OS (Women's Health Initiative Observational Study). A subcohort of 1300 black and 1500 white participants were randomly chosen as controls; a total of 550 black and 1500 white women who developed incident CVD during a mean follow-up of 11 years were chosen as cases. We directly measured total 25( OH )D, vitamin D-binding protein, albumin, parathyroid hormone, and calculated free and bioavailable 25( OH )D. Weighted Cox proportional hazards models were used to examine their associations with CVD risk. Although vitamin D-binding protein and total, free, and bioavailable 25( OH )D were not significantly associated with CVD risk in black or white women, a significant positive association between parathyroid hormone and CVD risk persisted in white women (hazard ratio comparing the highest quartile with the lowest, 1.37; 95% CI , 1.06-1.77) but not in black women (hazard ratio comparing the highest quartile with the lowest, 1.12; 95% CI, 0.79-1.58), independent of total, free, and bioavailable 25( OH )D or vitamin D-binding protein. Conclusions Circulating levels of vitamin D biomarkers are not related to CVD risk in either white or black women. Higher parathyroid hormone levels may be an independent risk factor for CVD in white women.
Identifiants
pubmed: 30764690
doi: 10.1161/JAHA.118.011021
pmc: PMC6405652
doi:
Substances chimiques
Biomarkers
0
Parathyroid Hormone
0
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e011021Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL113056
Pays : United States
Références
Nat Rev Cardiol. 2016 Jul;13(7):404-17
pubmed: 27150190
Age Ageing. 2014 Jul;43(4):528-35
pubmed: 24375224
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2204-2212
pubmed: 28882871
J Am Med Dir Assoc. 2010 Nov;11(9):617-28
pubmed: 21029996
Am Heart J. 2011 Aug;162(2):331-339.e2
pubmed: 21835295
J Clin Epidemiol. 1999 Dec;52(12):1165-72
pubmed: 10580779
Ann Epidemiol. 2003 Oct;13(9 Suppl):S18-77
pubmed: 14575939
PLoS One. 2010 Nov 09;5(11):e13882
pubmed: 21085485
JAMA. 2003 May 28;289(20):2673-84
pubmed: 12771114
N Engl J Med. 2007 Jul 19;357(3):266-81
pubmed: 17634462
Clin Chim Acta. 2016 Apr 1;455:154-60
pubmed: 26835752
J Clin Endocrinol Metab. 2017 Aug 1;102(8):3075-3084
pubmed: 28472285
Osteoporos Int. 2011 Jun;22(6):1745-53
pubmed: 20848081
J Clin Endocrinol Metab. 2013 Apr;98(4):E638-45
pubmed: 23408568
Am Heart J. 2013 May;165(5):655-64, 664.e1-5
pubmed: 23622902
Clin Chem. 2016 Jan;62(1):179-87
pubmed: 26453697
Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):819-29
pubmed: 23149428
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
pubmed: 10523012
J Bone Miner Res. 2011 Jul;26(7):1609-16
pubmed: 21416506
JAMA. 2013 Jul 10;310(2):179-88
pubmed: 23839752
Hypertension. 2007 May;49(5):1063-9
pubmed: 17372031
Ann Clin Biochem. 2017 Mar;54(2):199-208
pubmed: 27742848
Am Heart J. 2014 Sep;168(3):296-302
pubmed: 25173540
J Am Coll Cardiol. 2017 Jul 4;70(1):89-100
pubmed: 28662812
Ann Intern Med. 2003 Jul 15;139(2):137-47
pubmed: 12859163
Circ Heart Fail. 2014 Sep;7(5):732-9
pubmed: 25104043
J Am Heart Assoc. 2019 Feb 19;8(4):e011021
pubmed: 30764690
Biometrics. 1986 Jun;42(2):301-10
pubmed: 3741972
Circulation. 2012 Jul 3;126(1):50-9
pubmed: 22693351
J Clin Endocrinol Metab. 2013 Oct;98(10):E1583-90
pubmed: 23928672
Nutrition. 2012 Apr;28(4):367-71
pubmed: 22261577